| Date | Title | | | 01/28/10 | Celgene Reports Record Fourth Quarter and Full Year 2009 Product Sales and Operating Income|
Record Fourth Quarter and Full Year Results Driven By Gains in Global Market Share, Duration of Therapy and Reimbursement Approvals
REVLIMID(R) Fourth Quarter Global Net Product Sales Increased 35% Y/Y and 11% Q/Q
VIDAZA(R) Fourth Quarter Global Net Product Sales Increased 68% Y/Y and 13% Q/Q
Full Year Non-GAAP Diluted Earnings Per Share Increased 33% Y/Y
SUMMIT, N.J., Jan 28, 2010 (BUSINESS WIRE) -- Celgene Corporation (NASDAQ: CELG):
2009 Fourth Quarter Financial Results Year-Over-Y... |
|  | | 01/19/10 | Celgene Corporation to Announce Fourth Quarter and Full-Year 2009
Results on January 28, 2010| SUMMIT, N.J., Jan 19, 2010 (BUSINESS WIRE) -- Celgene Corporation (NASDAQ: CELG) senior management will host a
conference call and live audio webcast on Thursday, January 28, 2010 at
9 a.m. ET to discuss the company's fourth quarter and full-year 2009
financial and operational results. The webcast will be available in the
investor relations section of the company's Web site at www.celgene.com.
Celgene Corporation, headquartered in Summit, New Jersey, is an
... |
| | | 01/15/10 | Celgene Completes Acquisition of Gloucester Pharmaceuticals| Transaction completed for $340 million in cash with additional milestone opportunities of up to $300 millionCommercial Launch of Novel HDAC Inhibitor, ISTODAX(R) (romidepsin), for the Treatment of Cutaneous T-Cell Lymphoma (CTCL) Targeted For First Half of 2010SUMMIT, N.J., Jan 15, 2010 (BUSINESS WIRE) -- Celgene Corporation (NASDAQ: CELG) today announced it has closed its
acquisition of Gloucester Pharmaceuticals following the early
termination of the applicable waiting period u... |
| | | 01/12/10 | Intergroupe Francophone du Myelome (IFM) Phase III Study (IFM 2005
02) Evaluating Treatment with Continuous REVLIMID(R)
in Patients with Multiple Myeloma Following Autologous Stem Cell
Transplant Meets Primary Endpoint| BOUDRY, Switzerland, Jan 12, 2010 (BUSINESS WIRE) -- Celgene International Sàrl (NASDAQ: CELG) today announced that
the Intergroupe Francophone du Myelome and University Hospital of
Toulouse, the sponsor of the study, reported that the independent Data
and Safety Monitoring Committee, of the international Phase III,
randomized, double-blind, multi-center clinical study (IFM 2005 02)
evaluating REVLIMID(R) (lenalidomide) compared to placebo in
multi... |
| | | 01/11/10 | Celgene Corporation Reviews 2009 Achievements and Announces 2010
Financial Outlook| _ Record Fourth Quarter and Full Year Results Driven By Gains in Global Market Share, Duration of Therapy and Reimbursement Approvals î REVLIMID(R) Fourth Quarter Global Net Product Sales Increased Nearly 35% Y/Y î VIDAZA(R) Fourth Quarter Global Net Product Sales Increased Nearly 65% Y/Y î Full Year Non-GAAP Diluted Earnings Per Share Increased More Than 30 % Y/Y î Conducting 20 Phase III and Pivotal Clinical TrialsSUMMIT, N.J., Jan 11, 2010 (BUSINESS WIRE) -- Celgene Corporation (NASDAQ: CELG)... |
| | | 01/06/10 | Celgene Corporation to Present at the 28th
Annual JPMorgan Healthcare Conference| SUMMIT, N.J., Jan 06, 2010 (BUSINESS WIRE) -- Celgene Corporation (NASDAQ: CELG) today announced its
presentation at the 28th Annual JPMorgan Healthcare
Conference on Monday, January 11, 2010 at 8:00 AM PST (11:00 AM EST)
will be webcast live and will be available in the investor relations
section of the company's Web site at www.celgene.com.
Sol J. Barer, Ph.D., Chairman and Chief Executive Officer, will provide
an overview of the company.
Celgen... |
| |
|
